PGDx elio™: Empowering Local Insight for Oncology

 

PGDx has developed standardized clinical diagnostic NGS solutions for laboratories worldwide. Local testing and global access enable faster results to guide treatment decisions within the local patient care pathway.

 

 

PGDx elio™ Panels

PGDx elio™ tissue complete

  • Pan cancer for Tumor Profiling 
    • 500+ Full Coding Genes for Sequence Mutations
    • Complex Alterations including Indels, Amplifications, and Translocations
    • TMB and MSI
    • CE Marked
    • FDA Cleared
Contact Us For Information

PGDx elio™ plasma complete*

  • Pan Cancer for Biomarker Discovery 
    • 500+ Full Coding Genes for Sequence Mutations
    • Complex Alterations including Indels, Amplifications, and Translocations
    • LOH, MSI and TMB

*Research Use Only.

Contact Us For Information

PGDx elio™ plasma resolve*

  • Pan Cancer for Tumor Profiling 
    • 30+ Full Coding Genes for Sequence Mutations
    • Complex Alterations including Indels, Amplifications, and Translocations
    • MSI
    • CE Marked

    For U.S. Customers

For U.S. Customers.
*Research Use Only.

Contact Us For Information

*Research Use Only.

Contact Us For Information

Patient Care Ecosystem

Our products will integrate optimized assay chemistry with an automated bioinformatics platform, enabling consistent, actionable results. The PGDx elio platform will incorporate machine learning technology, supporting the delivery of more accurate somatic mutation detection compared to other methods. This approach is core to our vision of driving localized, standardized NGS, delivering faster turnaround of reliable results. 

PATIENT

  • Faster results to inform critical treatment decisions
  • Comprehensive genomic information from a single sample
  • Potential access to clinical trials